Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors Yutaka Ueda,Tatsu Shimoyama,et al. Cancer Chemother Pharmacol 2011;67:1101–1109
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68) Shizuo Machida, Yasushi Saga,et al. Int. J. Cancer 2005;114:224–229
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.